nmdar antagonist 1

NMDAR antagonist 1 is an orally active, NR2B-selective NMDAR antagonist.

(Rac)-NMDAR antagonist 1 is a racemate of NMDAR antagonist 1, a potent, orally active, NR2B-selective NMDAR antagonist.

GluN2B-NMDAR Antagonist-1, an orally active compound, functions as a GluN2B-NMDAR antagonist with neuroprotective properties. It is applicable in the research of ischemic injury [1].

MDAR IN-1 (Compound 5m) is a brain-penetrant acetylcholinesterase (AChE) inhibitor and an antagonist of the NMDAR receptor GluN1/GluN2B subtype. It effectively inhibits AChE activity, enhances cholinergic neurotransmission, and blocks NMDAR to reduce excitotoxicity. MDAR IN-1 shows potential for Alzheimer’s disease research.

NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker with an IC50 of 1.93 μM. It shows positive predicted blood-brain-barrier (BBB) permeability and can be used in Alzheimer's disease research[1].

Withaphysalin D, isolated from water lilies, is a selective antagonist for the N-methyl-D-aspartate receptor (NMDAR) containing GluN2B with neuroprotective properties. This compound is capable of crossing the blood-brain barrier [1].

6-Hydroxykynurenic acid (6-HKA), a kynurenic acid (KYNA) derivative isolated from Ginkgo leaves, functions as a low-affinity NMDAR antagonist with an IC50 of 59 μM [1].